Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.

about

G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database.

P2860

Q34982532-EA8EF365-A30F-4091-881C-5BD22A16805C Q48606842-6DCF458E-3C43-44E4-86A2-0207161E05EE

P2860

Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.

Item

http://www.wikidata.org/entity/Q42540897

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Primary prophylaxis with hemat ...... n cost-effectiveness analysis.

@en

Primary prophylaxis with hemat ...... n cost-effectiveness analysis.

@nl

type

Item

label

Primary prophylaxis with hemat ...... n cost-effectiveness analysis.

@en

Primary prophylaxis with hemat ...... n cost-effectiveness analysis.

@nl

prefLabel

Primary prophylaxis with hemat ...... n cost-effectiveness analysis.

@en

Primary prophylaxis with hemat ...... n cost-effectiveness analysis.

@nl

P1476

Primary prophylaxis with hemat ...... n cost-effectiveness analysis.

@en

P2093

Charles L Bennett

http://www.w3.org/2001/XMLSchema#string

Leann B Norris

http://www.w3.org/2001/XMLSchema#string

Michael Dickson

http://www.w3.org/2001/XMLSchema#string

Scott A Strassels

http://www.w3.org/2001/XMLSchema#string

P2860

Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma

Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.

Colony-stimulating factors for febrile neutropenia during cancer therapy.

Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.

Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.

Factors predicting Medicare national coverage: an empirical analysis.

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.

Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.

P304

1072-1073

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1093/JNCI/DJT198

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

250924946

http://www.w3.org/2001/XMLSchema#string

P698

23873406

http://www.w3.org/2001/XMLSchema#string

P932

3735465

http://www.w3.org/2001/XMLSchema#string

Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.

about

P2860

P2860

Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932